InnoCan Pharma Corporation

As of June 30, 2026, InnoCan Pharma Corporation carries a market capitalization of 11.25M, placing it among publicly traded companies globally. Its enterprise value stands at 8.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, InnoCan Pharma Corporation has 4.50M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.34, and the price-to-book ratio stands at 1.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.23M versus a market cap of 11.25M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, InnoCan Pharma Corporation maintains a current ratio of 5.25, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.45, indicating elevated leverage, while an interest coverage ratio of -130.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation posted a negative return on equity (ROE) of -21.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.95, reflecting losses generated across the asset base. The company generates approximately 3.71M in revenue per employee across its workforce of 9.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.94 indicates how many times InnoCan Pharma Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation recorded an income tax benefit of -59,606.82 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.24M and -1.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 15, 2026, InnoCan Pharma Corporation's stock has declined approximately 88.13% over the past 52 weeks. The 50-day moving average sits at 2.44, while the 200-day moving average is 7.98.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation generated 33.39M in revenue and converted that into -1.36M in net income, yielding earnings per share of -0.26. EBITDA reached -4.82M, while operating income came in at -4.87M.

As of June 30, 2026, InnoCan Pharma Corporation holds 9.08M in cash and equivalents against 2.36M in total debt, resulting in a net debt position of -6.72M. Total book value stands at 6.82M, with working capital of 11.82M providing operational flexibility.

InnoCan Pharma Corporation produced -2.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26,964.99 in capital expenditures, free cash flow totaled -2.20M - equivalent to -0.49 per share.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation posted a gross margin of 90.46, reflecting its pricing power and cost economics. The operating margin of -14.60 and net profit margin of -4.07 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.16, meaning InnoCan Pharma Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

InnoCan Pharma Corporation's most recent stock split took place on September 5, 2025 with a 65:1 split ratio.

As of June 30, 2026, InnoCan Pharma Corporation has an Altman Z-Score of -1.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.